Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Drugs & Targets

Merck pays $35M to Kelun-Biotech for rights to investigational antibody drug conjugate

July 29, 2022
Vol.48 No.30
Clinical Roundup

Merck to stop phase III LYNK-003 trial evaluating Lynparza with or without bevacizumab in metastatic colorectal cancer

July 22, 2022
Vol.48 No.29

Posts navigation

Previous1…34

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Michael Bishop, Nobel-winning cancer researcher, dies at 90
  • FDA issues warning letter to ImmunityBio over misleading claims about cancer drug
  • Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account